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he c-Myc oncoprotein is strongly induced during
the G0 to S-phase transition and is an important
regulator of cell cycle entry. In contrast to c-Myc,
the putative Myc antagonist Mnt is maintained at a con-
stant level during cell cycle entry. Mnt and Myc require
interaction with Max for speciﬁc DNA binding at E-box
sites, but have opposing transcriptional activities. Here,
we show that c-Myc induction during cell cycle entry
leads to a transient decrease in Mnt–Max complexes and
a transient switch in the ratio of Mnt–Max to c-Myc–Max
T
 
on shared target genes. Mnt overexpression suppressed
cell cycle entry and cell proliferation, suggesting that the
ratio of Mnt–Max to c-Myc–Max is critical for cell cycle
entry. Furthermore, simultaneous Cre-Lox mediated dele-
tion of 
 
Mnt
 
 and 
 
c-Myc
 
 in mouse embryo ﬁbroblasts res-
cued the cell cycle entry and proliferative block caused
by 
 
c-Myc
 
 ablation alone. These results demonstrate that
Mnt-Myc antagonism plays a fundamental role in regu-
lating cell cycle entry and proliferation.
 
Introduction
 
The oncogenic activity of Myc family proteins is initiated
when their transcriptional regulation is disrupted by events
such as gene amplification and gene translocation, which typi-
cally lead to elevated cellular Myc levels. Under normal condi-
tions, high c-Myc protein levels are produced only transiently
when cells enter the cell cycle and subsequently decline to low,
but detectable levels (Persson et al., 1984; Hann et al., 1985).
The significance of the transient burst of c-Myc expression
early during cell cycle entry is revealed by experiments showing
that ectopic c-Myc expression, by itself, can trigger quiescent
fibroblasts to enter the cell cycle (Eilers et al., 1991). However,
high Myc levels and its effects on cell proliferation are typically
not sustainable, as many cell types respond to this situation by
undergoing apoptosis. This is particularly the case when the
growth and survival factor environment is, or becomes, limiting
(Askew et al., 1991; Evan et al., 1992). Thus, both the up-regu-
lation of c-Myc and its subsequent down-regulation, function
as critical elements in the normal transition of quiescent cells to
proliferating cells.
Consistent with a key role for Myc proteins in stimulating
cell cycle entry, primary mouse embryo fibroblasts (MEFs)
lacking c-Myc accumulate in G0 of the cell cycle and are ren-
dered incompetent to proliferate in response to mitogenic stim-
ulation (de Alboran et al., 2001; Trumpp et al., 2001). In con-
trast to primary cells, deletion of c-
 
Myc
 
 in the “immortal”
Rat1A fibroblast cell line significantly slows, but does not ab-
rogate cell proliferation (Mateyak et al., 1997). The slowed
proliferation in the latter cells appears to be the result of both a
decreased rate at which cells traverse the cell cycle and a failure
of some cells to enter a productive cell cycle (Holzel et al.,
2001; Schorl and Sedivy, 2003). From these and many other
results, it can be concluded that deregulated and elevated Myc
production, so common in tumors, has the consequence of both
stimulating cells to enter the cell cycle and preventing cells
from properly exiting the cell cycle.
The ability of Myc family proteins to promote cell prolif-
eration and contribute to tumor formation is dependent on its
bHLHZip domain, which mediates heterodimerization with
Max and DNA binding (Blackwood and Eisenman, 1991). The
Myc–Max heterodimer, but not Myc alone, is able to bind
DNA at the E-box consensus sequence CANNTG and activate
transcription (Amati et al., 1992; Kretzner et al., 1992). In log-
arithmically proliferating cells it appears that most, if not all
newly synthesized c-Myc enters into a complex with Max and
that the rapid turnover of c-Myc protein (half-life of approxi-
mately 15 min) is not affected by heterodimerization with Max
(Blackwood et al., 1992). Together with results showing that
Max is a highly stable protein with a half-life in excess of 24 h
(Blackwood et al., 1992), these results support the idea that a
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pool of Max is always available for interaction with newly
synthesized c-Myc. However, in addition to Myc family pro-
teins, Max interacts with a number of additional bHLHZip
proteins that have the potential to limit the supply of Max for
Myc heterodimerization. Moreover, these additional Max-in-
teracting proteins, which include Mad family proteins (Mad1,
Mxi1, Mad3, and Mad4), Mnt, and Mga (Zhou and Hurlin,
2001), are transcriptional repressors that have been demon-
strated to antagonize Myc-dependent cell transformation in
cell culture experiments.
Mnt is unique among these putative Myc antagonists in
that it is expressed ubiquitously and like Max, Mnt levels do
not fluctuate during the G0 to S-phase transition (Hurlin et al.,
1997a, 2003). Importantly, Mnt appears to play a role in cell
cycle entry, as cells lacking Mnt were found to exhibit an ac-
celerated G0 to S-phase transition (Hurlin et al., 2003). These
results, together with the finding that deletion of Mnt can pre-
dispose cells in vivo to apoptosis and tumorigenesis (Hurlin et
al., 2003, Nilsson et al., 2004), suggest that Mnt–Max regula-
tion of Myc activity during cell cycle entry may endow it with
a unique role as a cellular Myc antagonist. In this study, we
investigate the role Mnt plays in cell cycle entry and provide
evidence that a transient switch in the ratio of Mnt–Max to
c-Myc–Max underlies the basic decision of cells to enter the
cell cycle and proliferate.
 
Results
 
Complex switching between Mnt–Max 
and c-Myc–Max during cell cycle entry
 
The accelerated G0 to S-phase transition exhibited by Mnt
null MEFs (Hurlin et al., 2003) suggested that the balance be-
tween Mnt–Max and c-Myc–Max complexes may regulate
proper cell cycle entry. Therefore we examined the relation-
ship between Mnt and c-Myc steady-state levels and complex
formation with Max during cell cycle entry of primary human
fibroblasts. Fibroblasts were driven into quiescence by a
combination of confluence arrest and serum starvation, then
stimulated to enter the cell cycle by the addition of 10% FCS.
Tritiated thymidine incorporation was used to confirm entry
into S-phase (unpublished data). Consistent with our previ-
ous results using primary MEFs, Mnt levels were maintained
at a near constant level during cell cycle entry (Fig. 1 a). As
expected, c-Myc levels were initially present at extremely
low levels in quiescent cells and rapidly, but transiently, in-
duced (Fig. 1 a). To examine Mnt–Max and c-Myc–Max
complex formation during cell cycle entry, low stringency
anti-Max immunoprecipitations were performed. Low strin-
gency anti-Max immunoprecipitations were treated with high
stringency buffer to elute bound proteins and secondary im-
munoprecipitations were performed on the eluates with anti–
c-Myc and Mnt antibodies (Hurlin et al., 1997a). Whereas
Max remained at near constant levels during cell cycle entry,
its interaction with Mnt and c-Myc fluctuated as a function of
c-Myc levels (Fig. 1 b). Although c-Myc and c-Myc–Max
levels increased from a very low level in unstimulated cells
to high levels at 4 h, a corresponding drop in Mnt–Max levels
occurred, despite near constant Mnt levels (Fig. 1 a). As c-Myc
and c-Myc–Max levels subsequently declined at 8 and 24 h
after serum stimulation, levels of Mnt–Max increased (Fig. 1 b).
These results suggest that induction of c-Myc to high levels
during the G0 to S-phase transition sets up a competition be-
tween c-Myc and Mnt for Max, that results in a limited sup-
ply of Max.
The presence of Mnt–Max complexes before c-Myc syn-
thesis during cell cycle entry suggested that the availability of
Max for newly synthesized c-Myc is, at least in part, a function
of the stability of the Mnt–Max complex. Although we previ-
ously showed that Mnt is a very short-lived protein (Hurlin et
al., 1997b), it was unknown whether the half-life of Mnt was
affected by interaction with Max. To address this question, we
used pulse-chase analysis combined with low stringency anti-
Max immunoprecipitations to examine the half-life of Mnt
Figure 1. Complex switching between Mnt–Max and c-Myc–Max during
cell cycle entry. (a) Western blot showing Mnt and c-Myc levels at 0, 4, 8,
and 24 h after serum stimulation of quiescent MEFs. (b) Levels of Mnt and
c-Myc found in low stringency anti-Max immunoprecipitations during cell
cycle entry. Note reduction in Mnt (and Mnt–Max complexes) at times of
high c-Myc levels. (c) Pulse-chase analysis of Mnt turnover when com-
plexed to Max. Cells were metabolically labeled with medium containing
[
35S]methionine (pulse) then “chased” with medium containing unlabeled
methionine. Mnt was immunoprecipitated under high stringency conditions
(representing total Mnt) or from low stringency Max immunoprecipitated
material at 0, 1, 2, and 4 h, as indicated, during the chase period. B,
immunogen blocked antibody. 
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when bound to Max. Consistent with previous results (Hurlin et
al., 1997b), endogenous Mnt protein exhibited a half-life of
 
 
 
20–30 min (Fig. 1 c). The profile of Mnt turnover when com-
plexed to Max was very similar to that observed under high
stringency conditions (Fig. 1 c). These results suggest that the
rapid turnover of Mnt, like that of c-Myc (Blackwood et al.,
1992), occurs while in a complex with the long-lived Max pro-
tein and determines the stability of Mnt–Max complexes.
Moreover, because the intensity of labeled Mnt immunoprecip-
itated under high stringency conditions was similar to that ob-
tained from Max complexes (Fig. 1 c), these results suggest
that most newly synthesized Mnt enters into a complex with
Max in logarithmically growing cells.
 
Switching between Mnt–Max and c-Myc–
Max binding at shared target genes 
during cell cycle entry
 
To directly examine the consequences of complex switching
between Mnt–Max and c-Myc–Max during cell cycle entry,
chromatin immunoprecipitation (ChIP) experiments were per-
formed. Early passage 
 
Mnt
 
 null and wild-type MEFs were
made quiescent and stimulated to enter the cell cycle as de-
scribed above. c-Myc expression was monitored by Western
blot (Fig. 2 a) and tritiated thymidine incorporation assays per-
formed in parallel to confirm cells were arrested and entered
into the cell cycle (not depicted). Binding to specific sites in a
number of known or suspected Myc target genes, including
 
Cdk4
 
, 
 
Cyclin D2
 
 (
 
ccnd2
 
), 
 
ODC
 
, 
 
E2F2
 
, 
 
Nucleolin
 
, 
 
Tert
 
, and
 
CAD
 
 (for review see Cole and McMahon, 1999) was deter-
mined in quiescent cells and at 4 and 24 h after serum stimula-
tion. One of several E-box–containing regions within the 
 
Cyclin
E1
 
 (
 
ccne1
 
) gene where no c-Myc or Mnt binding was observed
was used as a negative control.
As shown in Fig. 2 b, Mnt was bound at the 
 
Cdk4
 
, 
 
Cyclin
D2
 
, 
 
ODC
 
, 
 
Nucleolin
 
, 
 
E2F2
 
, 
 
Tert
 
, 
 
Nucleolin
 
, and 
 
CAD
 
 genes in
quiescent cells (0 h) and at 4 and 24 h after serum stimulation.
No signal was observed with either preimmune serum or in
Mnt null MEFs (Fig. 2 b). Consistent with the strong induction
of c-Myc observed in cells 4 h after serum stimulation (Fig. 2 b),
c-Myc binding at the same sites was strongest at 4 h (Fig. 2 a).
This was true in both wild-type and Mnt null MEFs. Very little
signal for c-Myc binding was present at 0 and 24 h, when c-Myc
levels were very low (Fig. 2 a). Like Mnt, signal for Max bind-
ing was consistently observed in both quiescent and serum-
stimulated cells at the promoter sites in Myc target genes (Fig.
2 b). Signal for Max binding at these promoter regions was also
readily detected in Mnt null MEFs, even at times when c-Myc
was not detected. The latter results suggest that either Max
homodimers and/or heterodimers with Max-interacting pro-
teins other than c-Myc and Mnt occupy the same promoter sites
at these times.
Previous resulted showed that Mnt interacts with Sin3 in
vitro and that deletion of Mnt’s Sin3 interaction domain abol-
ished its ability to repress transcription (Hurlin et al., 1997a;
Meroni et al., 1997). To examine endogenous Mnt-Sin3 in-
teractions as a function of cell cycle entry, low stringency
anti-Mnt immunoprecipitations were performed, followed by
immunoblotting with anti-Sin3A and Max antibodies. These re-
sults showed that Mnt interacts with Sin3 in vivo and that Mnt-
Sin3 interaction is not regulated during the cell cycle (Fig. S1,
available at http://www.jcb.org/cgi/content/full/jcb.200411013/
DC1). Furthermore, ChIP assays performed by first immuno-
precipitating with Mnt antibody, then reimmunoprecipitating
(Metivier et al., 2003) with either anti-Sin3A or anti-HDAC1
(an Sin3A associated protein; Ayer, 1999) demonstrated associ-
ation of Sin3A and HDAC1 with Mnt at Mnt-Myc binding re-
gions within the 
 
Cyclin D2
 
, 
 
Nucleolin
 
, and 
 
TERT
 
 genes (Fig. 2 c).
These results suggest that Mnt–Sin3–HDAC complexes are
present at Mnt binding sites in chromatin.
Figure 2. Mnt–Max and Myc–Max complex switching on shared target
genes. (a) Western blot showing c-Myc expression in wild-type (Mnt
 / )
and Mnt null (Mnt
 / ) MEFs at 0, 4, and 24 h after serum stimulation of
quiescent cells. (b) ChIP analysis, performed in parallel with the Western
blot shown in panel a, examining Mnt, c-Myc, and Max binding to spe-
cific E-box–containing regions in the Cdk4, Cyclin D2, ODC, Nucleolin,
Telomerase (Tert) E2F2, CAD, and Cyclin E1 genes at 0, 4, and 24 h after
serum stimulation. (c) Chromatin reimmunoprecipitation (ReIP) assays
showing the presence of Sin3A and HDAC1 at several Mnt-Myc target
genes. Pre, preimmune serum; Total, total input. 
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Mnt/c-Myc target gene regulation in the 
absence of Mnt
 
To determine how loss of Mnt affects transcription of c-Myc/
Mnt target genes, real-time RT-PCR was used to analyze tran-
script abundance for genes identified above or previously (Hur-
lin et al., 2003; Nilsson et al., 2004) in the context of cell cycle
entry. RNA was extracted from serum starved, quiescent Mnt
null and wild-type cells and at 4, 12, 16, 20, and 24 h after se-
rum stimulation. Levels of ARBP P0 RNA, encoded by a gene
whose transcription is not regulated during cell cycle entry
(Fig. 3; Humbert et al., 2000), was used to normalize all RT-
PCR values obtained. As expected, c-Myc RNA levels were
strongly induced in MEFs after serum stimulation (Fig. 3).
However, the dynamics of induction were different between
wild-type and 
 
Mnt
 
 null MEFs, with the latter cells showing
higher levels at 12 h, but lower levels at other time points. Mnt
and Max RNA levels, like their respective encoded proteins
(Hurlin et al., 2003), were maintained at a near constant level.
In contrast, expression levels of Nucleolin, E2F2, and CAD
RNA were consistently altered, with each showing markedly
increased levels in 
 
Mnt
 
 null MEFs, especially 12 h after serum
stimulation (Fig. 3). The E1F4E gene, a putative Myc target
gene (Jones et al., 1996) encoding elongation factor 4E, was
also up-regulated at the 12-h time point (Fig. 3), although we
have yet to identify Myc-Mnt binding sites in the mouse version
of this gene. In contrast, ODC levels were not significantly
affected by loss of Mnt. Interestingly, although the amplitude
of Cyclin D2 and CDK4 expression did not appear to be signif-
icantly affected by Mnt loss, the expression patterns of Cyclin
D2 and CDK4 in Mnt null MEFs appeared to reflect the accel-
erated cell cycle entry profile of these cells compared with
wild-type MEFs (Fig. 5; Hurlin et al., 2003).
 
Overexpression of Mnt suppresses cell 
cycle entry
 
The defective cell cycle entry of Mnt null MEFs (Hurlin et al.,
2003), together with the above findings, suggest that the ratio
of Mnt to c-Myc is key to proper cell cycle entry. To better de-
fine the relationship between levels of c-Myc and Mnt during
cell cycle entry, primary wild-type and Mnt null MEFs were in-
fected with Mnt-expressing retrovirus (pBabeMnt-HA), briefly
selected to remove noninfected cells, and cell proliferation and
cell cycle entry experiments performed. For proliferation as-
says, cells were plated at 1.5 
 
  
 
10
 
4
 
 cells per 60-mm dish and
counted on four consecutive days at 24-h intervals. As shown
in Fig. 4 (a and b), Mnt overexpression caused a significant de-
cline in the proliferation rate of wild-type and Mnt
 
 
 
/
 
 
 
 MEFs.
To examine how Mnt overexpression affects the G0 to
S-phase transition, tritiated [
 
3
 
H]thymidine incorporation assays
were performed after serum stimulation of confluence arrested
and serum starved cells. Consistent with previous results (Hur-
lin et al., 2003), 
 
Mnt
 
 null MEFs showed elevated tritiated thy-
midine incorporation 16 h after serum stimulation indicating
robust entry into S-phase (Fig. 4 c). In contrast, overexpression
of Mnt in both 
 
Mnt
 
 null and wild-type MEFs strongly sup-
pressed tritiated thymidine incorporation over the time period
Figure 3. Regulation of c-Myc/Mnt target
genes during cell cycle entry in the absence of
Mnt. RNA from wild-type and Mnt null primary
MEFs was harvested at the indicated times after
serum stimulation and quantitative real-time
RT-PCR assays performed in triplicate for the
indicated genes. The data are representative
of two or more independent experiments.
RNA levels of the ARBP P0 gene, which do not
change during cell cycle entry (not depicted),
were used to standardize samples. Fold ex-
pression values were calculated relative to the
0-h time point in wild-type cells for each gene
as previously described (Livak and Schmittgen,
2001). SDs are shown. 
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analyzed (Fig. 4 c). However, these cells did eventually reenter
the cell cycle and proliferate, albeit at a slowed rate (Fig. 4 b
and not depicted). Thus, Mnt overexpression impeded, but did
not completely prevent cell cycle reentry.
 
Mnt deficiency rescues proliferation 
arrest caused by c-Myc deletion in 
primary MEFs
 
To better define the relationship between Mnt and c-Myc in cell
proliferation and cell cycle entry, we examined the consequences
of acute, simultaneous deletion of both Mnt and c-Myc in pri-
mary MEFs. Crosses between 
 
Mnt
 
flox/flox
 
 (Hurlin et al., 2003)
and 
 
c-Myc
 
floxN/floxN
 
 mice (Trumpp et al., 2001) were performed to
generate mice containing homozygous floxed alleles for both
Mnt and c-Myc (
 
Mnt
 
/c-
 
Myc
 
dCKO
 
). MEFs were then isolated from
the latter mice and from 
 
Mnt
 
flox/flox
 
 mice and 
 
c-Myc
 
flox/flox
 
 mice.
MEFs at passage 1 were infected with adenovirus expressing Cre
recombinase and GFP. GFP expression indicated that 
 
 
 
95% of
cells were infected and PCR genotyping and Western blot analy-
sis confirmed that a very high percentage of floxed alleles were
successfully targeted (Fig. 5, a and b, not depicted). Proliferation
assays performed 48 h after infection cells confirmed previous
results (de Alboran et al., 2001; Trumpp et al., 2001) showing
that deletion of c-
 
Myc
 
 leads to rapid cessation of primary
MEF proliferation (Fig. 5 c). In contrast, primary MEFs in
which 
 
c-Myc
 
 and 
 
Mnt
 
 were simultaneously ablated continued to
proliferate (Fig. 5 c). Very similar results were achieved after
AdCre infection of immortal (i) 
 
Mnt
 
flox/flox
 
, i
 
c-Myc
 
flox/flox
 
, and
i
 
Mnt
 
-
 
c-Myc
 
dCKO
 
 MEF cell lines (Fig. 5 d). The latter cell lines
were developed by continuously passaging primary cell popula-
tions until they escaped senescence (Todaro and Green, 1963).
The ability of Mnt deficiency to rescue proliferation ar-
rest was further examined by fluorescent cell sorting of pro-
pidium iodide stained primary cells after AdCre infection
(Fig. 5 e). Consistent with the proliferation assays, the fraction
of cells in S-phase was dramatically reduced by deletion of
c-Myc, but increased to near wild-type levels in MEFs lacking
both c-Myc and Mnt. A substantial elevation of a sub-G1 frac-
tion of cells, which is consistent with apoptosis, was present in
 
Mnt
 
flox/flox
 
 MEF populations and, to a lesser extent, in 
 
Mnt
 
-
 
c-
Myc
 
dCKO
 
 MEFs, but not 
 
c-Myc
 
flox/flox
 
 MEFs (Fig. 5 e, arrows).
These results are consistent with previous results showing that
Mnt deficiency triggers apoptosis (Hurlin et al., 2003; Nilsson
et al., 2004).
To further characterize how 
 
Mnt
 
 deletion rescued prolif-
eration arrest caused by loss of c-Myc, a series of Western blots
were performed examining the expression of proteins that per-
form critical functions in cell cycle control (Fig. 6). From this
analysis, it was observed that several proteins up-regulated by
loss of Mnt, including Cyclin D2, Cyclin A, Cyclin B, Cyclin
E, and p107, were also up-regulated in 
 
Mnt/c-Myc
 
dCKO
 
 MEFs,
relative to their expression in c-Myc–deficient MEFs (Fig. 6).
In addition, pRB was hyperphosphorylated by Mnt deletion,
both in the presence and absence of c-Myc. These results sug-
gest that Mnt deletion rescues the proliferation arrest caused by
c-Myc deletion at least partly through up-regulation of critical
cell cycle regulatory proteins.
Interestingly, we found that 
 
c-Myc
 
 deletion caused down-
regulation of p53, p19
 
ARF
 
, and p27Kip1, but that these affects
were not reversed by simultaneous deletion of Mnt (Fig. 6).
Moreover, the acute effect of Mnt deletion on p53, p19
 
ARF
 
, and
BclX
 
L
 
 levels was minimal. This is in contrast to previous re-
sults, which showed strong up-regulation of p53 and P19
 
ARF
 
, as
well as BclX
 
L
 
 down-regulation, after siRNA knockdown of
Mnt, even in absence of c-Myc (Nilsson et al., 2004).
Finally, the relationship between Mnt and c-Myc specifi-
cally in the context of cell cycle entry was examined after AdCre-
mediated deletion of 
 
Mnt
 
, c-
 
Myc
 
, and 
 
Mnt
 
 plus 
 
c-Myc
 
 in pri-
mary MEF cell lines. Whereas ablation of 
 
c-Myc
 
 completely
blocked the ability of MEFs to enter S-phase, MEFs in which
 
c-Myc
 
 and 
 
Mnt
 
 were simultaneously ablated incorporated triti-
ated thymidine with kinetics similar to control AdCre-infected
MEFs (Fig. 7 a). Consistent with the observed rescue of cell
cycle entry kinetics, deletion of Mnt rescued the depressed
RNA levels of the Cyclin D2, E2F2, ODC, and Cyclin E
caused by c-Myc deletion (Fig. 7 b). Interestingly, Gadd45a, a
target of c-Myc repression was up-regulated during cell cycle
entry in the absence of c-Myc, but its regulation MEFs defi-
cient for both Mnt and c-Myc was similar to that observed in
wild-type cells (Fig. S2, available at http://www.jcb.org/cgi/
content/full/jcb.200411013/DC1). However, other putative tar-
gets of Myc repression were not similarly affected (Fig. S2).
Figure 4. Mnt overexpression slows cell proliferation and impedes cell
cycle entry. (a) Western blot showing expression of Ha-tagged Mnt
(anti-Ha set) in pBabeMntHa-infected MEFs (lanes 2 and 4) and endoge-
nous Mnt (anti-Mnt set) in MEFs infected with empty virus (lanes 1 and 3).
(b) Proliferation curve conducted for 4 d showing decline in proliferation
rate caused by Mnt overexpression in wild-type and Mnt null MEFs. Each
value is the average number of cells counted from three different dishes in
two separate experiments. (c) Analysis of cell cycle (S-phase) entry in wild-
type and Mnt null MEFs overexpressing Mnt. Tritiated thymidine incorpora-
tion was measured at the indicated number of hours after serum stimulation
of MEFs made quiescent by confluence arrest and serum starvation. Experi-
ments were performed at least twice in triplicate and averages are shown. 
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Discussion
 
In this study, we provide evidence that complex switching be-
tween Myc–Max and Mnt–Max governs proper entry into the
cell cycle. Whereas c-Myc expression is strongly, but tran-
siently, up-regulated during the transition of quiescent MEFs
into S-phase, Mnt is constitutively expressed throughout
cell cycle entry and in proliferating cells (Hurlin et al.,
2003). However, Mnt–Max complexes were found to decrease,
whereas c-Myc–Max levels increased during times of maxi-
mal Myc expression (Fig. 1). We interpret these data to sug-
gest that as c-Myc levels rise above a critical threshold during
cell cycle entry, competition between c-Myc and Mnt for bind-
ing to Max leads to a limiting supply of Max. A limiting supply
of Max is significant in this setting because it theoretically accel-
erates a switch from repressive Mnt–Max complexes to c-Myc–
Max complexes at shared target genes. Importantly, although the
constitutive expression of Mnt during cell cycle entry is postu-
lated to have a restrictive influence on c-Myc–Max complex for-
mation, the short half-life of the Mnt protein, even when com-
plexed with Max (Fig. 1 c), appears to ensure that a continuous,
but measured supply of Max is available for complex formation
with c-Myc or potentially other Max partners. As c-Myc levels
increase, it is also possible that limiting amounts of Max may
lead to Mnt engaging in alternative complexes such as with Mlx
(Meroni et al., 2000). However, we have not observed Mnt–Mlx
complexes in vivo (unpublished data).
The importance of maintaining a proper ratio of Myc to
Mnt during cell cycle entry is suggested by results showing that
overexpression of Mnt retards cell cycle entry and cell prolifer-
ation (Fig. 4) and loss of Mnt accelerates cell cycle entry (Figs.
Figure 5. Deletion of Mnt rescues proliferation arrest caused
by loss of c-Myc. (a) PCR genotyping of MEFs of the indicated
genotypes after infection with empty (E) adenovirus or Cre (C)
recombinase-expressing adenovirus. Note the PCR primers used
to detect deleted Mnt alleles do not discriminate from wild-type
and recombined Mnt alleles. (b) Western blot examining Mnt
and c-Myc expression after AdCre infection of the indicated ge-
notypes. (c and d) MEF proliferation curves after deletion of
Mnt, c-Myc, and Mnt plus c-Myc in primary MEFs (c) and im-
mortal MEFs (d). Values shown in c and d are the average of
cell counts obtained from triplicate plates and are representative
of results obtained from two independent experiments. (e) Cell
cycle profiles generated from FAC sorting of propidium iodide
stained cells 48 h after AdCre infection of the indicated cell
lines. % of cells in S-phase (S) is shown. Arrows highlight sub G1
(growth phase 1) fractions consistent with apoptosis.
Figure 6. Effect of acute Mnt, c-Myc, and Mnt plus c-Myc deletion on the ex-
pression levels of proteins involved in the regulation of cell proliferation. Cell
extracts were obtained from primary MEFs after AdCre-mediated deletion of
Mnt, c-Myc, or both Mnt and c-Myc as shown in Fig. 5 (a and b). Western
blots were performed with antibodies against the indicated proteins.
4 and 5; Hurlin et al., 2003). Moreover, the notion that Mnt and
c-Myc function as a binary system to regulate cell cycle entry
and proliferation is firmly supported by the ability of Mnt dele-
tion to rescue the proliferative arrest caused by c-Myc ablationMNT REGULATES CELL CYCLE ENTRY • WALKER ET AL. 411
in primary and immortal MEFs (Fig. 5). It is important to stress
however, that Mnt ablation in primary and immortal MEFs does
not completely rescue the proliferative block caused by loss of
c-Myc (Fig. 5). Although increased apoptosis after Mnt deletion
(Fig. 5; Hurlin et al., 2003; Nilsson et al., 2004) may be respon-
sible for the partial, instead of full rescue of primary MEFs, it is
also possible that antagonism of Myc by Mad family proteins
or other unknown mechanisms may contribute as well.
While this work was in progress, it was reported that
siRNA-mediated knockdown of Mnt in Myc-deficient immor-
tal Rat1A fibroblasts (Mateyak et al., 1997) rescued the slow
proliferation of these cells (Nilsson et al., 2004). However,
whereas deletion of c-Myc in the Rat1A cell line causes
slowed proliferation, deletion of c-Myc in primary and in im-
mortal c-Myc
flox/flox MEFs caused a complete block in prolifer-
ation (MEFs; Fig. 5, c and d; de Alboran et al., 2001; Trumpp
et al., 2001). These results suggest that Rat1A cells acquired
defects over the course of their extensive growth in culture that
partially substitute for loss of c-Myc. The possibility and per-
haps likelihood that such acquired defects affect cell cycle
control, argue that primary or “freshly” immortalized Mnt/
c-Myc
dCKO MEFs are better suited to rigorously establish the
relationship between c-Myc and Mnt in governing cell cycle
entry and cell proliferation.
It should also be noted that there are significant differ-
ences observed between siRNA-mediated knockdown of Mnt
(Nilsson et al., 2004) and Cre-mediated Mnt gene deletion in
the regulation of gene targets and downstream effector protein
levels. Whereas siRNA-mediated knockdown of Mnt is associ-
ated with a dramatic down-regulation of antiapoptotic BclXL
and strong up-regulation of pro-apoptotic p19
ARF and p53 pro-
tein levels and ODC RNA and protein levels (Nilsson et al.,
2004), we find that chronic Mnt deletion or acute Mnt deletion
in primary MEFs has only a modest or no effect on their ex-
pression levels. (Figs. 3, 6, and 7; Hurlin et al., 2003). More-
over, siRNA-mediated Mnt knockdown was found to dramati-
cally down-regulate p27
Kip protein levels in Myc
 /  Rat1A
fibroblasts, NIH3T3s, and MEFs (Nilsson et al., 2004), but we
surprisingly find that p27
Kip1 levels are up-regulated as a result
of both chronic and acute deletion of Mnt, as well as in tumors
caused by Mnt deletion in vivo (Fig. 6; Fig. S2; and not de-
picted). It is not clear why these differences are seen, but they
are likely due to nonspecific effects associated with the differ-
ent methods used to remove Mnt.
The displacement of Mnt–Max complexes in favor of
c-Myc–Max complexes at shared target genes during cell cycle
entry (Fig. 2) is consistent with the proposal that Myc–Max
complexes operate, at least in part, by derepressing Mnt–Max
Figure 7. Analysis of cell cycle (S-phase) entry
after acute deletion of Mnt and Mnt plus c-Myc.
(a) Tritiated thymidine incorporation (counts/
minute) were determined at the indicated times
after serum stimulation of immortal MEFs made
quiescent by confluence arrest and serum dep-
rivation. (b) Quantitative real-time RT-PCR
analysis of Cyclin D2, E2F2, ODC, and Cyclin
E1 gene expression after serum stimulation.
Both tritiated thymidine and RT-PCR experi-
ments were performed in triplicate and SDs
are shown.JCB • VOLUME 169 • NUMBER 3 • 2005 412
bound target genes (Hurlin et al., 1997a, 2003; Nilsson et al.,
2004). Although it is unlikely that Mnt–Max and c-Myc–Max
complexes bind to and regulate exactly the same set of target
genes, we find that they do bind and regulate at least a subset of
overlapping target genes (Figs. 2, 3, and 7). What remains un-
clear is the precise relationship between c-Myc and Mnt binding
and transcriptional status. For example, we have been unable to
establish a clear link between the presence of Mnt at different
target genes and local histone acetylation status (not depicted),
despite being able to detect Mnt–Sin3 and presumably Mnt–
Sin3–HDAC interactions at target gene binding sites (Fig. 2).
However, chromatin deacetylation at the Cyclin D2 gene does
appear to correspond to Mnt binding (unpublished data). What-
ever the mechanism of Mnt repression, the finding that acute Mnt
deletion rescues, at least partially, the severe down-regulation of
Myc targets such as Cyclin D2 and E2F2 caused by acute c-Myc
deletion in primary MEFs (Fig. 7 b) is consistent with Mnt and
c-Myc functioning as a repression-activation system to regulate
the expression of critical target genes involved in cell cycle pro-
gression. Although we observe strong down-regulation of some
Myc target genes after c-Myc deletion, others such as ODC
were only modestly down-regulated (Fig. 7 b). The slight affect
on ODC levels are consistent with studies showing that most
Myc target genes are only modestly affected by loss of c-Myc in
immortal Rat1A cells (Bush et al., 1998; Cole and McMahon,
1999). Furthermore, transcript levels of most of the various Myc
target genes examined in this and previous studies were only
modestly affected by loss of Mnt (Fig. 3; Hurlin et al., 2003;
Nilsson et al., 2004). One potential explanation for these find-
ings is that the transcriptional activity of Mnt and Myc is inher-
ently weak (Eisenman, 2001) and that their biological impact
derives from eliciting small changes in the expression levels of
perhaps thousands of transcriptional targets (for reviews see
Fernandez et al., 2003; Orian et al., 2003; Cawley et al., 2004;
see http//www.myc-cancer-gene.org). Alternatively, transcrip-
tional regulation of Myc and Mnt target genes may be con-
strained to specific physiological settings that have yet to be
fully recognized. For example, during cell cycle entry in Mnt
null MEFs, up-regulation of target genes was most apparent 12 h
after serum stimulation (Fig. 3). Thus, because c-Myc binding to
target gene promoters was observed by 4 h after serum stimula-
tion (Fig. 2 b), secondary events, perhaps related to cell cycle–
regulated binding of other transcription factors to DNA or to
Myc, may dictate the time and amplitude of Myc-dependent
transcription activation (Cole and McMahon, 1999). The differ-
ent responses in gene expression observed in Mnt-deficient cells
may also reflect the existence of different classes of Myc target
genes (Haggerty et al., 2003). The development of MEF cell
lines containing conditional, floxed alleles of Mnt, c-Myc, and
both Mnt and c-Myc (Fig. 5) should prove useful for more pre-
cisely defining the mechanisms that underlie the regulation of
specific target genes by Myc and Mnt.
Although up-regulation of c-Myc expression plays an im-
portant role in stimulating cell cycle entry, it is of paramount
importance that it is then rapidly down-regulated. Sustained
high level Myc expression is not well tolerated and sensitizes
cells to apoptosis and tumorigenesis (Pelengaris et al., 2002;
Nilsson and Cleveland, 2003). Because both Myc–Max and
Mnt–Max complexes are present in cells during the normal
proliferative cell cycle (Hurlin et al., 1997a), we speculate that
Myc-driven apoptosis and tumorigenesis results when the
proper balance between Myc–Max and Mnt–Max in cells is
breached. This idea is strongly supported by results showing
that loss of Mnt triggers a “Myc-like” response of accelerated
proliferation and apoptosis in fibroblasts and leads to tumor
formation when deleted in breast epithelium (Hurlin et al.,
2003) and T cells (unpublished data). Though it is not yet clear
whether tumor formation caused by loss of Mnt is mechanisti-
cally equivalent to that caused by Myc, our results establish
that Myc-Mnt antagonism underlies the basic decision of cells
to enter the cell cycle and proliferate.
Materials and methods
Immunoprecipitation and Western blot studies
Low and high stringency immunoprecipitation conditions were performed
as previously described (Hurlin et al., 1997a). Antibodies included anti-
Mnt (affinity-purified H6823; Hurlin et al., 2003), anti-Max (Cruz C-17;
Santa Cruz Biotechnology, Inc.), and anti c-Myc (N-262; Santa Cruz Bio-
technology, Inc.). Max antibody was blocked using Gst-Max (Blackwood
et al., 1992). In addition to the above antibodies, the following antibodies
were used in Western blots: Cyclin D1, Cyclin D2, Cyclin E1, Cyclin A1,
Cyclin B, Cdk4, p107, p53, tubulin (all obtained from Santa Cruz Bio-
technology, Inc.), pRb, phospho-ser 807/811 Rb, (Cell Signaling),
p27Kip1, p21Cip1, BclXL (BD Biosciences), and p19ARF (AbCam).
Generation of MEFs
MEFs were obtained from Mnt null and Mnt
flox/flox (Hurlin et al., 2003; Toyo-
oka et al., 2004), c-Myc
flox/flox (Trumpp et al., 2001), and Mnt
flox/flox  
c-Myc
FloxN/FloxN (or Mnt
 /CKO   c-Myc
 /CKO) embryos at embryonic day 13.5
as previously described (Hurlin et al., 2003). Immortal MEF cell lines were
established by continuous passaging of cultures using a 3T9 protocol (To-
daro and Green, 1963). Genotyping of cells was performed by PCR. Primer
sets for the c-Myc locus were previously described (Trumpp et al., 2001).
Cell cycle entry and proliferation assays
For cell cycle entry experiments, MEFs or HFFs were grown to confluence
and switched from medium containing 10% FCS to medium containing
0.1% FCS. Cells were maintained in 0.1% FCS for 2–3 d before stimulat-
ing with medium containing 10% FCS. Tritiated thymidine incorporation
assays were performed in triplicate in 6-well dishes. The cells were la-
beled by incubating in 2 ml DME containing 1  Ci/ml methyl [
3H]thymi-
dine (ICN Biomedicals) for 2 h at 37 C, 5% CO2. Cells were washed
twice with ice-cold PBS and incubated for 20 min at 4 C in 5% TCA to re-
move acid soluble radioactivity. The cells were washed twice with 70%
EtOH and solubilized for 30 min at 37 C in 1 ml 0.1 M NaOH, 2%
Na2CO3, and 1% SDS. 5 ml of Ecolume scintillation cocktail (ICN Biomed-
icals) was added to lysates and counts per minute determined using a
scintillation counter (model LS5000TD; Beckman Coulter). Proliferation as-
says were performed as previously described (Hurlin et al., 2003).
ChIP analysis
For cell cycle entry assays, cells from four 150-mm tissue culture dishes
(containing cells to grown to confluence, serum starved and serum stimu-
lated) were washed once with PBS and fixed with 1.5% formaldehyde
(in PBS) for 5 min at 37 C. Fixed cells were collected, lysed, sonicated to
attain an average length of 750–1,200 bp, and immunoprecipitations
were performed using equal amounts of sonicated lysates. Immunoprecipi-
tations, washes, and elution of immunoprecipitated material were per-
formed as previously described (Metivier et al., 2003). Preimmune serum
was used as a negative control. Re-immunoprecipitations of primary immu-
noprecipitations were performed as described by Metivier et al. (2003)
and PCR (30–35 cycles) was performed on equal amounts of eluate.
Antibodies used for ChIP experiments included affinity-purified anti-Mnt
(H6823), c-Myc (N-262), Max (C-17), Sin3A (AK-11) were obtained from
Santa Cruz Biotechnology, Inc., and HDAC1 (2E10) was obtained from
Upstate Biotechnology.MNT REGULATES CELL CYCLE ENTRY • WALKER ET AL. 413
Real-time PCR
RNA was harvested using TRIzol reagent (Invitrogen), purified for mRNA
using oligotex particles (QIAGEN), and quantified by spectrophotometer.
0.5  g mRNA per sample was random primed using Superscript II reverse
transcriptase (Invitrogen). Samples in triplicate were amplified using SYBR
green I dye in an Applied Biosystems 7900HT sequence detection system.
Analysis of data was performed using the 2
   Ct method (Livak and Schmitt-
gen, 2001) and quantitated relative to the ARBO PO gene. Gene expres-
sion was normalized to unstimulated (0 time point) wild-type samples,
which provided an arbitrary constant for comparative fold expression.
Online supplemental material
Fig. S1 shows co-immunoprecipitation of Mnt and Sin3 in cells. Low strin-
gency (LS) Mnt immunoprecipitates were separated by SDS-PAGE and
Western blots performed using the antibodies against the indicated pro-
teins. Max was used as a positive control for Mnt interaction and high
stringency (HS) Mnt immunoprecipitates were used as a negative control.
Fig. S2 shows expression of Myc repression targets during cell cycle entry
of MEFs deficient in either Mnt, c-Myc, or both Mnt and c_Myc. RNA was
harvested at the indicated times after serum stimulation and real-time RT-
PCR performed for the indicated genes. Experiments were performed in
triplicate and SDs are shown. Online supplemental material is available at
http://www.jcb.org/cgi/content/full/jcb.200411013/DC1.
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